Nowadays computers are an essential part of modern pharmaceutical research and data storage. It is also well known that experimental and observational data is crucial for scientific research. For approximately twelve years now, the pharmaceutical industry is storing its research data on portable storage media, where each research group was obligated to archive their research data on such portab...

Volume 5(6) 1000e123 J Cancer Sci Ther ISSN:1948-5956 JCST, an open access journal The landmark decision to rejection of patent to anti-cancer drug ‘Glivec’ by Indian Supreme Court has catalysed range of debates around importance of innovation in research and development. The patent plea by Novartis for beta crystalline for of imanitib (i.e. glivec) was considered as an attempt to extend period...

Kaposi’s Sarcoma-Associated Herpesvirus ORF54/dUTPase downregulates a ligand for the NK 1 activating receptor NKp44 2 Alexis Madrid and Don Ganem# 3 4 1 Howard Hughes Medical Institute and GW Hooper Foundation Laboratories 5 University of California, San Francisco CA 94143 6 7 2 Novartis Institutes for Biomedical Research 8 Emeryville, CA 94608 9 10 #Corresponding Author 11 Novartis Institutes ...

MC Sophia Children’s Hospital, Rotterdam, the Netherlands (m.otten@erasmusmc .nl). Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Otten reported receiving travel grants from Pfizer (formerly Wyeth); and serving as a consultant to Roche. Dr Prince reported serving as a consultant to Bristol-Myers Squ...

Affiliations Department of Medical Oncology and Center for Cancer Genome Discovery, DanaFarber Cancer Institute, Boston, MA, USA Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA The Broad Institute, Cambridge, MA, USA Division of Cancer Therapeutics, Institute of Cancer Research, London, SW7 3RP, United Kingdom Corresponding author Levi A. Garraway, ...

ID=78016. 261. Novartis drug Afinitor met primary endpoint ofphase III study in women with advanced breastcancer; potential to address significant unmetneed. [internet]. Basel (Switzerland): Novartis;2011 Jul 5 [accessed 2011 Aug 1]. [6 p].Available:http://www.novartisoncology.com/media/pressreleases.jsp?id=1528340&year;=2011&page;=1. 262. Bachelot T, Bourgier C, Cropet C,...

Disclosure: Prof Matthias Kramer is an employee of Allergy Therapeutics UK Ltd. Prof Ralph Mösges has received consulting and/or speaker’s fees from, and/or conducted contract research for, several companies including ALK, Allergopharma, Bencard, Dr Beckmann, BioTechTools, HAL, Leti, Lofarma, Novartis, Roxall, Merck, and Stallergènes. Prof Randolf Brehler has received consulting and/or speaker‘...

lowing: Bausch & Lomb Inc, Notal Vision, Novartis Pharma AG, Roche/Genentech Inc, and Regeneron Pharmaceuticals Inc. Dr N. M. Bressler is a principal investigator of grants at Johns Hopkins University sponsored by the following: Abbott Medical Optics Inc, Alimera Sciences, Allergan USA, Inc, Bausch & Lomb Inc, Carl Zeiss Meditec Inc, ForSight Labs, LLC, Genzyme Corp, Lumenis Inc, Notal Vision, ...